Complications of myeloma and its treatments

Pleural effusion formation in the course of myeloma. Comert M etal. Arch Bronconeumol. 2015 Jan 22. pii: S0300-2896(14)00242-7. doi: 10.1016/j.arbres.2014.05.009. [Epub ahead of print]. Diagnosis of monoclonal gammopathy of renal significance. Bridoux F et al. Kidney Int. 2015 Jan 21. doi: 10.1038/ki.2014.408. [Epub ahead of print]. Paralytic ileus following “subcutaneous bortezomib” therapy: focus on the clinical emergency-report of two cases. Mele…

Details

Current treatments

An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma. Nishihori T et al. Eur J Haematol. 2015 Jan 20. doi: 10.1111/ejh.12509. [Epub ahead of print]. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myelomanot eligible for or who deferred autologous stem cell transplantation.…

Details

Results of Cancer Drugs Fund’s list reassessment announced

The results of a reassessment of the nationally approved list of drugs made available through the Cancer Drugs Fund (CDF) have been announced by NHS England. They confirm that Imnovid® (pomalidomide) for relapsed and refractory myeloma patients; Revlimid as a second-line treatment, and Velcade® as treatment for multiply relapsed Velcade-naive patients will remain on the list whereas…

Details

Diagnostic tests and prognostic indicators

Heavy/Light Chain Assay for Monitoring IgA Multiple Myeloma: Digging Out the IgA from the β Region. Calderon B et al. Clin Chem. 2014 Dec 10. pii: clinchem.2014.234757. [Epub ahead of print]. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Mithraprabhu S et al. Epigenetics. 2014 Dec 6:0. [Epub ahead of print]. Calorimetric markers of bence jones and nonsecretory multiple…

Details

Related conditions

Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. Manasanch EE et al. Haematologica. 2014 Dec;99(12):1769-71. doi: 10.3324/haematol.2014.107516. Disseminated sclerotic bone lesions with normal 18F-FDG uptake in POEMS syndrome. Shi X et al. Leuk Lymphoma. 2014 Dec 2:1-9. [Epub ahead of print]. Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge.…

Details

Emerging treatments

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. Stewart AK et al. N Engl J Med. 2014 Dec 6. [Epub ahead of print]. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, inmultiple myeloma patients. Carmon L et al. Br J Haematol. 2014 Dec 11. doi: 10.1111/bjh.13245. [Epub ahead of print]. The potential role of PD0332991 (Palbociclib) in the…

Details

Biology and genetics

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. Gomez-Bougie P et al. Cancer Biol Ther. 2014 Dec 17:0. [Epub ahead of print]. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Nijhof IS et al. Haematologica. 2014 Dec 15. pii: haematol.2014.117531. [Epub ahead of print]. Doxorubicin Overcomes Resistance…

Details

General

The Role Of P2X Receptors In Bone Biology. Jorgensen NR et al. Curr Med Chem. 2014 Dec 14. [Epub ahead of print]. A joined role of canopy and reversal cells in bone remodeling – Lessons from glucocorticoid-induced osteoporosis. Jensen PR et al. Bone. 2014 Dec 10. pii: S8756-3282(14)00456-6. doi: 10.1016/j.bone.2014.12.004. [Epub ahead of print]. Multiple myeloma and chronic leukaemias in 2014: Improved…

Details

Complications of myeloma and its treatments

Bortezomib-induced acute pancreatitis: Case report and review of the literature. Talamo G et al. J Oncol Pharm Pract. 2014 Dec 15. pii: 1078155214563813. [Epub ahead of print]. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. Teh BW et al. Support Care Cancer. 2014 Dec…

Details